Direct answer
Gut supplements need a specific indication. Soluble fiber and lactose-matched lactase have practical uses; peppermint and probiotics have variable evidence and commercial ties. ACG advises against probiotics for global IBS symptoms, while detox and cure claims lack reliable clinical support.
- Psyllium (soluble fiber) has the strongest guideline-backed evidence among gut supplements — ACG recommends it specifically over insoluble fiber for IBS symptoms.
- Probiotic evidence is specific to strains, doses and outcomes and is inconsistent in IBS. Some positive trials have commercial support; ACG advises against probiotics for global IBS symptoms, and AGA limits their IBS use to clinical trials. Source 1. Source 2.
- Saccharomyces boulardii has real evidence for preventing antibiotic-associated diarrhea — a distinct, well-supported indication, not general IBS treatment.
- Lactase and alpha-galactosidase work, but only for their specific indications (lactose intolerance and bean-related gas respectively) — not as general “digestive enzyme blend” wellness products.
- Detox cleanses, colon cleanses, “leaky gut cure” stacks, and apple-cider-vinegar miracle claims have no reliable independent evidence and can cause harm.
Table of contents
- Evidence summary
- The bottom-line ranking
- All forms and types of gut-health supplements
- What works
- What is mixed or overhyped
- What does not work
- Mechanisms: why some work and others do not
- Risks and reported side effects
- Interactions and precautions
- Who should avoid these supplements
- What works / does not verdict table
- Independent evidence and money trail
- Frequently asked questions
- Sources and publishing notes
Evidence summary
| Supplement or claim | Evidence | Primary source | Funding / conflict trace | Verdict |
|---|---|---|---|---|
| Psyllium / soluble fiber for IBS symptoms. | ACG recommends soluble fiber, not insoluble fiber, for global IBS symptoms; older meta-analysis supports fiber as a class but psyllium is preferred over bran. | ACG IBS guideline; Ford et al., BMJ | ACG reports no guideline financial support, but authors disclose pharmaceutical consulting, grants, equity and licensing relationships. Review/trial financing needs separate checks. | WORKS Source |
| Enteric-coated peppermint oil for IBS pain/spasm. | Meta-analyses suggest benefit for global IBS symptoms and pain with very low evidence certainty; one RCT had mixed primary versus secondary endpoint results. | 2022 peppermint oil meta-analysis record; Weerts et al. RCT | Weerts: Dutch ZonMw grant plus WillPharma capsules, related study funding and commercial licensing/consulting ties. Meta-analysis finances and underlying trials remain incompletely verified. | WORKS / MIXED Source |
| Bifidobacterium infantis 35624 for IBS. | A commercially linked women-only RCT found benefit at one dose. The recovered meta-analysis lists 35624 in all three single-strain trials and found no significant pooled benefit for those products. Its two combination trials used other multi-strain formulations, so their benefits cannot be assigned specifically to 35624. | Whorwell et al.; B. infantis 35624 meta-analysis | Whorwell’s authors report public grants and Procter & Gamble support, with four P&G employee authors, Alimentary Health ties and P&G product preparation. This is commercially conflicted evidence. The recovered B. infantis meta-analysis reports no funding, waived publication-support fees and no author competing interests; this does not establish the financing of its included trials. | SELECTED USE Source 1 Source 2 |
| Bifidobacterium bifidum MIMBb75 for IBS. | RCTs of viable and heat-inactivated MIMBb75 report IBS symptom improvement; WGO lists this strain with evidence level 2 for IBS. | Guglielmetti et al.; Andresen et al.; WGO guideline | The 2020 heat-inactivated trial explicitly names Synformulas funding. The original authors’ reply names Naturwohl Pharma funding for the 2011 viable-strain trial. | PRODUCT-SPECIFIC, COMMERCIALLY FUNDED CONTEXT Source |
| Lactiplantibacillus plantarum 299v for IBS. | One RCT reported improvement in abdominal pain and bloating; another RCT found no significant abdominal pain relief difference, so the evidence is not uniform. | Ducrotté et al.; Stevenson et al./RCT record | Ducrotte: Rosell-Lallemand Institute and Probi AB support; Rosell-Lallemand supplied study products. Stevenson’s original paper reports partial funding from Nestlé Nutrition Institute Africa and the South African NRF (grant 2075266), with no competing interests declared. Ferlot manufactured the active and placebo capsules; purchase or donation terms are not reported. Original author-uploaded paper. | MIXED Source 1 Source 2 |
| Saccharomyces boulardii for antibiotic-associated diarrhea prevention. | Systematic review with meta-analysis found reduced antibiotic-associated diarrhea risk; this is not the same as proving IBS benefit. | S. boulardii AAD meta-analysis | The review was funded by the Medical University of Warsaw; Hania Szajewska declared speaking work for Biocodex, the manufacturer of S. boulardii. | WORKS for selected indication |
| Prebiotics for IBS. | No consistent global IBS benefit; lower doses and prebiotics other than inulin-type fructans showed limited flatulence signals, while inulin-type fructans worsened flatulence. | Wilson et al.; NCCIH IBS review | The review was part of a doctoral fellowship funded by Clasado Biosciences, a prebiotic supplement company; authors report no company role in the review. They also disclose other public, charitable and commercial research grants. Included-trial financing needs separate assessment. Original review disclosures. | MIXED Source |
| Lactase for lactose intolerance. | Human enzyme replacement trials show improved lactose digestion and lower breath hydrogen after lactose exposure. | adult lactase deficiency trial; comparative lactase trial | The 1984 trial acknowledges enzyme donations from SugarLo and G.B. Fermentation Industries. Complete cash funding and author relationships for these older trials remain unverified; their findings apply to lactose maldigestion, not all bloating. | WORKS |
| Alpha-galactosidase for gas. | Meal-challenge evidence supports reduced intestinal gas after bean challenge; IBS symptom trial evidence is mixed. | Di Stefano et al.; IBS alpha-galactosidase trial | The Di Stefano study includes a Promefarm-affiliated coauthor; complete funding and product procurement remain unverified. Use these trials only for their food-specific gas or separately studied IBS claims. | INDICATION-SPECIFIC |
| Generic “digestive enzyme blends” for daily bloating. | Evidence is much stronger for diagnosed enzyme problems than for broad wellness blends. | digestive enzyme supplementation review; PERT review | Review evidence includes medical indications; broad supplement blends often lack independent testing. | INSUFFICIENT |
| Detox, juice cleanse, and colon cleanse claims. | NCCIH says detox evidence is low quality; colonic cleansing systematic review found no rigorous support for health promotion and reports adverse effects. | NCCIH detox/cleanse fact sheet; Acosta & Cash | NCCIH is a public clinical reference. Acosta & Cash report no financial support. Cash chaired the ACG Public Relations Committee, whose members reviewed and approved drafts. | DOESN’T Source |
| Apple cider vinegar as a gut-health miracle. | Small studies address glycemia or delayed gastric emptying, not microbiome repair or IBS cure; injury case reports and product variability raise safety concerns. | gastroparesis pilot study; ACV tablet injury report | Clinical records do not establish a gut-health indication; commercial claims are usually marketing extrapolations. | DOESN’T for gut-health cure claims |
Choose by Symptom, Not by Hype
What is the main pattern?
Hard stools / IBS-C: consider psyllium.
IBS pain / spasm: consider a peppermint oil trial after safety review.
Milk-triggered symptoms: consider lactase or lactose evaluation.
Bean-triggered gas: alpha-galactosidase has meal-specific evidence.
Antibiotic-associated diarrhea risk: S. boulardii only when appropriate and without its contraindications.
Red flags or malabsorption: medical evaluation first.
Skip detoxes, colon cleanses, ACV miracle shots and generic “leaky gut cure” stacks.
Text version of this infographic
Choose gut supplements by symptom pattern. Hard stools or IBS-C points to psyllium; IBS pain or spasm may justify an enteric-coated peppermint oil trial; milk-triggered symptoms point to lactase or lactose testing; bean-triggered gas may justify alpha-galactosidase; antibiotic-associated diarrhea prevention may justify S. boulardii only when appropriate; red flags or malabsorption require medical evaluation first. Skip detoxes, colon cleanses, apple-cider-vinegar miracle shots, and generic leaky gut cure stacks.
The bottom-line ranking
All forms and grades
| Category | Common forms | What it is | Best use | Verdict |
|---|---|---|---|---|
| Bulk-forming soluble fibers | Psyllium husk powder/capsules, ispaghula, partially hydrolyzed guar gum. | Water-holding fibers that change stool texture and fermentation patterns. | IBS-C, mixed stool patterns, constipation tendency. | Works best when titrated slowly. |
| Fermentable prebiotics | Inulin, FOS, GOS, resistant starch, acacia fiber. | Substrates intended to feed selected microbes. | Selected constipation or microbiome-feeding goals. | Mixed in IBS; gas risk is real. |
| Probiotics | Capsules, sachets, fermented milks, freeze-dried bacteria, probiotic yeast. | Live microorganisms intended to confer a health benefit at adequate amounts. | Named strain for named outcome. | Strain-specific; generic claims fail. |
| Synbiotics | Probiotic plus prebiotic combinations. | A live microbe paired with a substrate. | Occasionally studied for specific outcomes. | Do not assume combo is better. |
| Postbiotics / heat-killed microbes | Heat-inactivated strains, microbial metabolites, cell-wall preparations. | Non-living microbial preparations or metabolites. | Emerging; MIMBb75 heat-inactivated strain has IBS RCT evidence. | Promising but product-specific. |
| Botanical antispasmodics | Enteric-coated peppermint oil, peppermint blends, carminative teas. | Plant oils or herbs used for spasm/gas symptoms. | Enteric-coated peppermint oil for IBS pain/spasm. | Peppermint has evidence; blends vary. |
| Digestive enzymes | Lactase, alpha-galactosidase, pancreatic enzymes, broad blends with amylase/protease/lipase, papain/bromelain. | Enzymes that break specific nutrients into smaller molecules. | Specific enzyme gap or diagnosed disease. | Works only when matched to substrate/disease. |
| “Gut lining” formulas | L-glutamine, collagen, zinc carnosine, aloe, slippery elm, marshmallow root, butyrate salts. | Products marketed to “seal” or “repair” the intestinal barrier. | Research context or specific diagnoses, not generic cure claims. | Insufficient for leaky-gut cure marketing. |
| Acid/fermentation tonics | Apple cider vinegar shots/gummies, kombucha concentrates, bitters. | Acidic or fermented products sold for digestion or metabolism. | Food preference, not IBS or microbiome cure. | Overhyped; ACV has safety issues. |
| Cleanses | Juice cleanses, laxative teas, colon hydrotherapy, coffee enemas, detox kits. | Programs marketed to remove toxins or reset the bowel. | No routine gut-health role. | Doesn’t work and can harm. |
What works
Psyllium: the most practical IBS fiber
Psyllium works because it holds water, forms a gel, and improves stool consistency without the same rapid fermentation burden as many prebiotic powders. ACG recommends soluble fiber but not insoluble fiber for global IBS symptoms, making psyllium a better first supplement than wheat bran for IBS-type symptoms (ACG guideline).
Take psyllium with the amount of fluid specified on its label; MedlinePlus advises at least 240 mL for powder or granules. People with swallowing difficulty or intestinal blockage need medical advice, and inhaled powder can cause allergic reactions. Source.
Enteric-coated peppermint oil: useful for selected IBS pain
Peppermint oil is a smooth-muscle antispasmodic, and the active menthol-rich oil can reduce intestinal spasm in some IBS patients. A 2022 updated meta-analysis found possible benefit but rated the evidence very low quality and reported more adverse events, while a 2020 randomized trial found mixed results because primary endpoints were not significantly different even though some secondary pain and discomfort outcomes improved (peppermint meta-analysis, Weerts trial).
The evidence applies mainly to enteric-coated products studied for IBS, not peppermint candy, essential oil drops, or peppermint tea. Peppermint oil can cause or worsen heartburn and reflux, so people with GERD or hiatal hernia should seek advice and stop if symptoms worsen (peppermint safety review).
Lactase: works when lactose is the problem
Lactase supplements help digest lactose, and older controlled human trials showed improved lactose digestion and reduced breath hydrogen after lactose-containing meals (adult lactase deficiency trial, comparative lactase trial). Lactase is a good example of an evidence-based enzyme because the enzyme, substrate, symptom trigger, and outcome all match.
Alpha-galactosidase: works best for a narrow food-gas problem
Alpha-galactosidase can reduce gas production from alpha-galactoside-rich foods such as beans in challenge settings, but IBS symptom trials are mixed (Di Stefano et al., IBS alpha-galactosidase trial). It is reasonable as a targeted meal tool, not as proof that chronic bloating is caused by a generalized enzyme deficiency.
Pancreatic enzymes: medical treatment, not wellness trend
Pancreatic enzyme replacement therapy is used for diagnosed exocrine pancreatic insufficiency, where fat maldigestion, weight loss, greasy stools, or pancreatic disease may be present. Evidence for PERT should not be transferred to over-the-counter enzyme blends for ordinary bloating (PERT review, digestive enzyme supplementation review).
Evidence vs Hype Matrix
Compare indication-specific human evidence with the claims made for each product; financial disclosures and clinical limitations appear in the tables.
Evidence varies for psyllium fiber, peppermint oil, lactase, specific probiotics and prebiotic powders. Generic leaky-gut cure stacks, wellness colon cleanses and ACV miracle claims lack an established clinical benefit.
Text version of this infographic
The evidence-versus-hype matrix places psyllium, lactase, and peppermint oil toward the higher-evidence side; specific probiotics and prebiotic powders in the mixed middle; and leaky-gut cure stacks, colon cleanses, and apple-cider-vinegar miracle claims in the high-hype, low-evidence area.
What is mixed or overhyped
Specific probiotics: possible, but not generic
A real probiotic claim must name the strain, dose, outcome, and population. NCCIH states that different probiotics can have different effects and that if one Lactobacillus helps prevent an illness, another Lactobacillus or Bifidobacterium cannot be assumed to do the same (NCCIH probiotics safety).
For IBS, WGO lists B. bifidum MIMBb75 and L. plantarum 299v as strains with IBS evidence, and WGO’s older IBS guidance noted B. infantis 35624 as having one of the better IBS evidence bases, but ACG still recommends against routine probiotics for global IBS symptoms because the overall evidence is heterogeneous and low certainty (WGO probiotics/prebiotics guideline, WGO IBS guideline, ACG guideline).
Multi-strain probiotic hype
More strains and more CFU are not automatically better because strains can differ in survival, dose-response, metabolites, immune effects, and clinical endpoints. A probiotic label with 15 organisms but no matching RCT for the exact formula is weaker evidence than a modest single-strain product tested for the same condition.
Prebiotics: helpful substrate, not always IBS-friendly
Prebiotics do not consistently improve global IBS symptoms. In one meta-analysis, some lower-dose products and prebiotics other than inulin-type fructans showed limited flatulence benefits, while inulin-type fructans increased flatulence. Source.
Fermented foods and kombucha concentrates
Fermented foods are foods, not automatically probiotics. A review found limited clinical evidence for most fermented foods in gastrointestinal disease and noted that several popular fermented foods lacked RCT evidence for GI health at the time of review (Dimidi et al.). Publication was supported by a Danone grant to ESNM, and the review discloses author relationships with food and supplement companies. A 2024 kombucha clinical study was funded by GT’s Living Foods LLC and involved an author on its scientific advisory board, so it should not be treated as independent proof for kombucha supplement claims (kombucha clinical study).
Probiotic Label Checklist
- Full identity: genus + species + strain, not just “Lactobacillus blend”
- Dose: CFU or viable count through end of shelf life
- Outcome match: IBS, antibiotic-associated diarrhea, constipation, etc.
- Safety fit: avoid self-use if immunocompromised, critically ill, or central-line patient
Fail rule: If the label cannot answer these four questions, the claim is marketing, not evidence.
Text version of this infographic
A probiotic label should provide: full identity with genus, species, and strain; dose or viable count through end of shelf life; outcome match such as IBS or antibiotic-associated diarrhea; and safety fit for the user. If the label cannot answer these four questions, the claim is marketing rather than evidence.
What does not work
Detox cleanses and juice cleanses
NCCIH states that detox and cleanse studies in people are few and low quality, and that some programs can be unsafe or falsely advertised (NCCIH detox/cleanse fact sheet). Juice cleanses can also expose susceptible people to high oxalate loads, unpasteurized-juice pathogens, low calorie intake, and delayed medical care for real digestive disease (NCCIH detox/cleanse fact sheet).
Colon cleanse and colon hydrotherapy
A systematic review in the American Journal of Gastroenterology found no methodologically rigorous controlled trials supporting colonic cleansing for general health promotion and noted multiple case reports and case series of adverse effects (Acosta & Cash). Colon cleansing is not a microbiome reset; it is a risk-containing procedure or laxative exposure without a wellness indication.
“Leaky gut supplement cures”
Intestinal permeability is a real research topic, but “leaky gut syndrome” cure marketing often jumps from mechanism to supplement stack without diagnostic criteria or outcome proof. The original narrative review on “leaky gut” ingredients reports no external funding and no author conflicts, but it is still a narrative-style ingredient review and does not prove that consumer gut-lining stacks cure IBS, autoimmune disease, fatigue, or food intolerance (leaky gut ingredients review, leaky gut myths review).
Apple cider vinegar miracle claims
Apple cider vinegar has been studied more for glycemic response and gastric emptying than for IBS or microbiome restoration. In a small pilot study of people with type 1 diabetes and gastroparesis, apple cider vinegar delayed gastric emptying further, and a separate report described esophageal injury and large quality variation among apple cider vinegar tablets (gastroparesis pilot study, ACV tablet injury report).
Mechanisms: why some work and others do not
Effective gut supplements usually have a clear target. Psyllium changes stool water and viscosity; peppermint oil relaxes intestinal smooth muscle; lactase digests lactose; alpha-galactosidase digests specific bean oligosaccharides; and pancreatic enzymes replace missing pancreatic digestive activity.
Weak gut supplements usually rely on vague claims. “Detox” rarely names the toxin, dose, test, endpoint, or excretion pathway; “leaky gut cure” rarely proves a diagnosed permeability abnormality and clinical improvement; and multi-strain probiotic hype often skips the exact strain-and-outcome evidence required by probiotic science.
Risks and reported side effects
| Ingredient / category | Reported or possible effects | Serious risks or diagnostic cautions | At-risk populations | Independent source |
|---|---|---|---|---|
| Psyllium | Stomach discomfort, nausea or other bowel symptoms may occur. | Difficulty breathing or swallowing, rash, vomiting or stomach pain need prompt medical advice. | Swallowing difficulty, intestinal blockage, inadequate fluid intake or psyllium allergy. | MedlinePlus psyllium clinical advice Source |
| Peppermint oil | Heartburn/reflux, nausea, peppermint taste or anal irritation may occur; frequencies depend on the preparation. | Allergic reactions and worsening reflux are possible. | GERD or hiatal hernia may worsen. Colpermin lists liver/biliary disease and gallstones as contraindications; age limits vary by authorised product. | Peppermint review; Colpermin label |
| Probiotics including Lactobacillus, Bifidobacterium, and S. boulardii. | Gas, bloating or stool changes may occur; rates vary by product and population. | Severe infections can occur in vulnerable people. S. boulardii can cause fungemia or sepsis. | Seek specialist advice with severe illness, immune compromise or premature infancy. S. boulardii medicines are contraindicated in central-venous-catheter, critically ill and immunocompromised patients. EMA assessment | NCCIH probiotics safety |
| Prebiotics: inulin, FOS, GOS, resistant starch. | Flatulence, bloating, abdominal pain, cramps and diarrhea, especially at high adult doses above 20 g/day. | The cited guidance does not establish a rate of severe reactions; persistent diarrhea needs clinical advice. | People with IBS-related bloating or undergoing a supervised low-FODMAP trial should discuss tolerance and dose. | NCCIH IBS review |
| Lactase. | Generally minimal; symptoms can persist if dose is too low for lactose load. | Masking another diagnosis if symptoms are not truly lactose-related. | Milk allergy, unexplained weight loss, anemia, persistent diarrhea, children with growth issues. | lactase trial |
| Alpha-galactosidase. | Variable GI response, bloating changes, discomfort. | An IBS trial had more withdrawals for pain or diarrhea with the enzyme than placebo. | Persistent or severe IBS symptoms need assessment; people taking carbohydrate-active diabetes medicines should ask their prescriber because this combination was not tested in the cited trial. | gas-production trial; IBS trial Source |
| Pancreatic enzymes. | Adverse effects depend on the prescribed preparation and dose; consult its medicine label. | High doses and disease-specific risks require specialist assessment; the cited abstract does not verify this complete risk list. | Diagnosed pancreatic insufficiency: use prescribed enzymes with clinician-guided meals and dosing. | PERT review Source |
| Apple cider vinegar shots/tablets/gummies. | Acidic tablets can injure the esophagus; symptoms and product acidity vary. | A small gastroparesis trial found further delayed gastric emptying. These cited papers do not verify every proposed electrolyte or drug effect. | Gastroparesis or swallowing problems; discuss persistent symptoms with a clinician. | gastroparesis pilot study; ACV tablet injury report Source 1 Source 2 |
| Detoxes, laxative cleanses, colon hydrotherapy. | Diarrhea, cramps, nausea, dizziness, dehydration. | Electrolyte disorders, infection, kidney injury, bowel perforation, burns/inflammation, delayed diagnosis. | Kidney disease, heart disease, GI disease, diabetes, pregnancy, older adults, immunocompromised people. | NCCIH; colonic cleansing review |
Interactions and precautions
| Ingredient | Interacts with | Mechanism / direction | Severity | Action |
|---|---|---|---|---|
| Psyllium | Digoxin, aspirin/salicylates and nitrofurantoin; discuss all other medicines with a pharmacist. | MedlinePlus advises avoiding these three medicines within three hours of psyllium; other spacing depends on the medicine. | Medication-specific precaution. | Follow the medicine label and pharmacist advice. Source |
| Peppermint oil | Antacids, PPIs and H2 blockers with enteric-coated capsules. | The authorised Colpermin label warns acid suppression can release the coating early; formal interaction studies were not performed. | Product-specific precaution. | Follow the exact product label and ask a pharmacist about spacing; stop if reflux worsens. Colpermin label |
| Peppermint oil | Cyclosporine; other transplant medicines require prescriber review. | A rat study increased cyclosporine exposure; the magnitude and clinical relevance in humans are not established. | Preclinical concern; clinical uncertainty. | Do not self-combine with transplant medicines. Original rat study |
| Probiotic bacteria | Antibiotics. | Antibiotics can kill susceptible probiotic bacteria and reduce intended viability. | Timing issue. | Separate dosing if a clinician recommends use. |
| S. boulardii | Oral or systemic antifungal medicines. | The authorised Ultra-Levura label says not to use these together because the probiotic is a live yeast. | Avoid concomitant use; separate serious infection contraindications. | S. boulardii medicines are contraindicated in central-venous-catheter, critically ill and immunocompromised patients. Ultra-Levura label; EMA safety assessment |
| Prebiotics | Low-FODMAP elimination trials and individual food tolerance. | Fermentable prebiotics can increase gas and affect interpretation of a dietary symptom trial. The cited evidence does not establish specific laxative, antidiarrheal or diabetes-drug interactions. | Diet and dose tolerance issue. | Discuss the product and dose during a supervised dietary trial; avoid adding high-dose inulin casually. Prebiotic review |
| Lactase | Lactose-containing meals. | Desired effect: hydrolyzes lactose into absorbable sugars. | Low. | Use only with lactose exposure; persistent symptoms need evaluation. |
| Alpha-galactosidase | Acarbose or miglitol; diabetes regimens. | The cited IBS trial did not test these drug combinations; any concern is an unverified precaution, not a demonstrated interaction. | Use with caution. | Ask prescribing clinician if using carbohydrate-active diabetes medication. Source |
| Pancreatic enzymes | Meal fat content, acid suppression plans, disease-specific medicines. | Effect depends on timing with meals and disease state; inappropriate use can obscure diagnosis. | Clinician-guided. | Use for diagnosed pancreatic insufficiency under medical supervision. |
| Apple cider vinegar | Diabetes treatment when gastroparesis affects meal or medicine timing. | Small pilot data show further delayed gastric emptying in type 1 diabetes with gastroparesis; specific drug and potassium interactions were not established by these papers. | Avoid using it as a gastroparesis treatment. | Discuss meal and medicine timing with the treating clinician. Source |
| Detox/laxative cleanses | Medicines and illnesses affected by fluid or electrolyte changes. | Cleanses can cause diarrhea, dehydration or dangerous electrolyte imbalance; the cited guidance does not verify an exhaustive drug-by-drug interaction list. | Avoid for wellness. | Do not use for gut health; medical bowel preparation and medicine adjustments should be clinician-directed. NCCIH safety guidance |
Interaction Risk Map
Cleanses: dehydration or electrolyte imbalance can complicate illness and medicine use.
Probiotics in vulnerable patients: infection risk; S. boulardii has specific contraindications.
Psyllium: spacing depends on the individual medicine.
Enteric-coated peppermint with acid-reducing medicines: possible early capsule release.
ACV with gastroparesis: further delayed gastric emptying.
Prebiotics during a low-FODMAP trial: possible extra gas and difficult symptom interpretation.
Ask a pharmacist or prescriber before adding a supplement to important ongoing treatment.
Text version of this infographic
High-risk combinations include cleanses with heart or kidney drugs because of electrolyte shifts and dehydration; probiotics in severe immune-risk patients because of infection or fungemia concern; psyllium with critical medicines because of absorption changes; peppermint oil with reflux medicines because of early release or heartburn; apple cider vinegar with gastroparesis or diabetes therapy because of delayed gastric emptying; and prebiotics during low-FODMAP testing because they confound the symptom trial. If a medicine prevents rejection, clots, seizures, arrhythmia, pregnancy, infection, or glucose emergencies, do not add gut supplements casually.
Who should avoid these supplements
People with blood in stool, black stools, unexplained anemia, unintentional weight loss, fever, persistent vomiting, nighttime diarrhea, severe dehydration, trouble swallowing, progressive symptoms, or new major bowel changes should seek medical evaluation before using gut supplements. ACG supports targeted testing for celiac disease and inflammatory bowel disease in relevant IBS presentations rather than assuming all digestive symptoms are functional (ACG guideline).
People who are immunocompromised, critically ill, premature infants, central-line patients, or recovering from major GI injury should avoid self-prescribed probiotics because NCCIH reports severe or fatal infections in premature infants and serious complications in people with underlying health problems (NCCIH probiotics safety).
People with reflux, gastroparesis, swallowing problems, gallbladder disease, kidney disease, heart disease, or complex medication regimens should be especially cautious because peppermint oil, apple cider vinegar, psyllium, and cleanses can worsen symptoms or interact with treatment.
What works / does not verdict table
| Claim | Verdict | Evidence | Key caveat |
|---|---|---|---|
| Psyllium improves IBS-C or mixed stool patterns. | WORKS | ACG recommends soluble fiber for global IBS symptoms (ACG guideline). | Needs fluid and medication separation. |
| Enteric-coated peppermint oil helps IBS pain/spasm. | WORKS / MIXED | Meta-analyses suggest benefit with very low evidence certainty, while newer RCT data are mixed on primary endpoints (peppermint meta-analysis, Weerts trial). | Reflux-prone people may do worse. |
| B. infantis 35624 helps every IBS patient. | MIXED | A dose-specific women-only trial was positive; the cited meta-analysis found no significant pooled benefit in three single-strain 35624 trials; results from its two multi-strain mixtures cannot be attributed specifically to 35624. | Evidence cannot be generalized to other Bifidobacterium strains. Source 1 Source 2 |
| B. bifidum MIMBb75 has IBS trial support. | PRODUCT-SPECIFIC CONTEXT | Viable and heat-inactivated strain trials reported symptom improvement (Guglielmetti et al., Andresen et al.). | 2020 Synformulas funding; not independent proof or routine use for all IBS. Source |
| L. plantarum 299v is proven for all IBS. | MIXED | One RCT was positive and another did not show significant abdominal pain relief (Ducrotté et al., Stevenson et al. 2014). | Trial length, population, and endpoints matter. |
| S. boulardii prevents antibiotic-associated diarrhea. | WORKS for selected users | Meta-analysis supports reduced antibiotic-associated diarrhea risk (S. boulardii meta-analysis). | S. boulardii medicines are contraindicated in immunocompromised, critically ill or central-venous-catheter patients. EMA safety assessment |
| Prebiotic powder improves IBS. | MIXED | Evidence varies by type and dose; inulin-type fructans can increase flatulence in IBS (NCCIH IBS review). | Start low and avoid during low-FODMAP elimination. |
| Lactase helps lactose intolerance. | WORKS | Controlled trials showed improved lactose digestion (lactase trial). | Only helps lactose-triggered symptoms. |
| Alpha-galactosidase helps all bloating. | MIXED | Bean challenge evidence is positive; IBS symptom evidence is mixed (gas trial, IBS trial). | Best as meal-specific support. |
| Digestive enzyme blends fix poor digestion. | INSUFFICIENT | Evidence is indication-specific for lactase or pancreatic enzymes, not broad wellness blends (digestive enzyme review). | Persistent symptoms need diagnosis. |
| Leaky-gut supplement stacks cure IBS or autoimmune symptoms. | INSUFFICIENT | Barrier function is real, but consumer cure claims exceed clinical evidence (leaky gut ingredients review, leaky gut myths review). | Do not use to replace diagnosis or treatment. |
| Colon cleanses reset the gut. | DOESN’T | No rigorous evidence supports colonic cleansing for general health promotion (Acosta & Cash). | Can cause serious adverse effects. |
| Apple cider vinegar cures digestion or microbiome problems. | DOESN’T | Evidence does not support IBS or microbiome cure claims; safety reports include delayed gastric emptying and esophageal injury (gastroparesis pilot, ACV injury report). | Especially risky in reflux or gastroparesis. |
Independent evidence and money trail
Research funding at a glance
9 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
| Evidence source | Country / type | Funding and conflict check | Independence rating | Credibility rank | Used for |
|---|---|---|---|---|---|
| ACG IBS guideline | United States professional society guideline. | Guideline financial support: none reported. Authors disclose pharmaceutical consulting, research grants, equity and licensing ties. | Author industry ties; guideline recommendations interpreted with evidence certainty. | Useful guideline with conflict caveats. | IBS fiber, peppermint, probiotic, low-FODMAP context. Source |
| NCCIH probiotics safety | United States public-health agency. | Official NCCIH clinical guidance; this page does not identify its specific funding or individual author disclosures. | Public guidance; independence not inferred from agency status. | Very strong. | Probiotic safety and strain-specific warning language. |
| WGO probiotics/prebiotics guideline | Global professional guideline. | The original guideline does not provide a complete author-financial declaration or guideline-specific sponsor trace. Its product tables are checked against the cited trials. | Financial independence not established; useful framework with product-specific limits. | Moderate–Strong. | Probiotic definition, strain specificity, selected IBS strains. |
| B. infantis 35624 RCT | Clinical trial. | Authors’ reported support includes public grants and Procter & Gamble; four authors are P&G employees, with additional Alimentary Health ties. | Commercially conflicted. | Moderate. | Used only as strain-specific evidence. |
| B. bifidum MIMBb75 RCT | Clinical trial. | 2020 trial funded by Synformulas; Guglielmetti disclosed consulting fees from Synformulas outside the submitted work, and Israelitic Hospital received study-site reimbursement. The funder reportedly had no role in design, data, analysis or writing. Original 2020 paper. The 2011 authors’ reply declares Naturwohl Pharma funding and no personal interests. | Synformulas funded the 2020 trial; Naturwohl Pharma funded the 2011 trial. | Context only for commercial outcome evidence. | Used only for MIMBb75, not probiotic category claims. Source |
| Peppermint oil meta-analysis | Academic systematic review. | Complete review financing, author disclosures and underlying trial funding were not verified. | Unknown; not established independent. | Systematic review with access and trial-conflict limitations. | Peppermint oil efficacy and safety. Source |
| Prebiotic meta-analysis | Academic systematic review. | Clasado Biosciences funded the doctoral fellowship supporting this review. Authors report that the company had no role in the decision, design, implementation, analysis or interpretation, and disclose other public, charitable and industry research grants. Included-trial finances have not been fully verified. Original review disclosures. | Commercially supported review; context only. | Systematic review; limited subgroup findings and trial-finance gaps. | Prebiotic uncertainty. Source |
| NCCIH detox/cleanse fact sheet | United States public-health agency. | Official NCCIH safety guidance; this page does not identify its specific funding or individual author disclosures. | Public guidance; independence not inferred from agency status. | Very strong. | Detox, cleanse, juice, and colon-cleanse safety. |
| Kombucha controlled study | Clinical study. | Conflicted: funded by GT’s Living Foods LLC and one author served on the company scientific advisory board. | Conflicted. | Downgraded. | Example of why fermented supplement claims need funding checks. |
Money-Trail Rule for Gut Claims
Product owner funds a trial.
One strain or formula shows benefit.
Marketing may generalize this to “all probiotics work.”
Use the exact studied product and indication, disclose commercial relationships, assess study methods and avoid category-wide extrapolation.
Text version of this infographic
The money-trail rule: when a product owner funds a trial and one strain or formula shows benefit, marketing often leaps to “all probiotics work” or “all gut products work.” The editorial response is to cite the exact product or strain only, downgrade conflicts, and reject category-wide extrapolation.
Frequently asked questions
What gut supplement has the best evidence?
Psyllium has the best practical evidence for common IBS/constipation-type use because ACG recommends soluble fiber for global IBS symptoms. Lactase is also strong when lactose is the confirmed trigger, and peppermint oil may be reasonable for selected adults with IBS pain or spasm, with very low evidence certainty (ACG guideline, lactase trial, peppermint meta-analysis).
Are multi-strain probiotics better?
Not automatically. NCCIH explains that different probiotic types can have different effects, so one strain’s benefit cannot be generalized to another strain or blend; a multi-strain label without exact formula evidence is usually weaker than a named strain studied for the same outcome (NCCIH probiotics safety).
Which probiotic strains have IBS evidence?
Human IBS trials have tested B. infantis 35624, MIMBb75 and L. plantarum 299v, with inconsistent results. Some have commercial support, including Synformulas funding and Rosell-Lallemand/Probi support. ACG suggests against probiotics for global IBS symptoms, with very low evidence certainty. Source 1. Source 2. Source 3.
Do prebiotics help or hurt IBS?
Both are possible. The cited review found no consistent global IBS benefit; certain lower-dose products and prebiotics other than inulin-type fructans showed limited flatulence signals, while inulin-type fructans worsened it. Source.
Do digestive enzyme blends work?
Digestive enzymes work when matched to a specific substrate or disease, such as lactase for lactose or pancreatic enzymes for pancreatic insufficiency. Broad blends marketed for everyday bloating have much weaker evidence and should not replace evaluation for persistent symptoms (lactase trial, PERT review).
Can apple cider vinegar improve gut health?
Apple cider vinegar is not an evidence-based IBS or microbiome treatment. It can delay gastric emptying and has been associated with esophageal injury in tablet form, so miracle digestion claims are not worth the risk for people with reflux, gastroparesis, or swallowing problems (gastroparesis pilot study, ACV tablet injury report).
Are colon cleanses good for gut health?
No. NCCIH warns that detoxes and cleanses can be unsafe, and a systematic review found no rigorous evidence supporting colonic cleansing for general health promotion (NCCIH detox/cleanse fact sheet, Acosta & Cash).
What is the safest way to test a gut supplement?
Test one evidence-matched supplement at a time, define the target symptom, use a short trial window, record stool pattern and pain/bloating changes, and stop if side effects occur. Do not self-test supplements when red flags, immunosuppression, central venous catheters, pregnancy complications, severe reflux, kidney disease, heart disease, or complex medicines are present.
Sources and publishing notes
- Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021.
- Su GL, Ko CW, Bercik P, et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020.
- World Gastroenterology Organisation. Probiotics and Prebiotics Global Guideline. 2023.
- NCCIH. Probiotics: Usefulness and Safety.
- NCCIH. Irritable Bowel Syndrome and Complementary Health Approaches.
- Whorwell PJ, et al. Efficacy of Bifidobacterium infantis 35624 in women with IBS. Am J Gastroenterol. 2006.
- Efficacy of Bifidobacterium infantis 35624 in IBS: meta-analysis. PubMed.
- Guglielmetti S, et al. Bifidobacterium bifidum MIMBb75 in IBS. Aliment Pharmacol Ther. 2011.
- Andresen V, et al. Heat-inactivated Bifidobacterium bifidum MIMBb75 in IBS. Lancet Gastroenterol Hepatol. 2020.
- Ducrotté P, et al. Lactobacillus plantarum 299v in IBS. World J Gastroenterol. 2012.
- Randomized clinical trial: Lactobacillus plantarum 299v on IBS symptoms. PubMed.
- Systematic review with meta-analysis: Saccharomyces boulardii in antibiotic-associated diarrhea. PubMed.
- Wilson B, Rossi M, Dimidi E, Whelan K. Prebiotics in IBS and functional bowel disorders. Am J Clin Nutr. 2019.
- Systematic review and meta-analysis: efficacy of peppermint oil in IBS. PubMed.
- Weerts ZZRM, et al. Efficacy and safety of peppermint oil in IBS. Gastroenterology. 2020.
- Review article: physiologic effects and safety of peppermint oil. PMC.
- Enzyme replacement therapy for primary adult lactase deficiency. PubMed.
- Comparative effects of exogenous lactase preparations on lactose digestion. PubMed.
- Di Stefano M, et al. Oral alpha-galactosidase and intestinal gas production. PubMed.
- Does oral alpha-galactosidase relieve irritable bowel symptoms? PubMed.
- Digestive enzyme supplementation in gastrointestinal diseases. PMC.
- Pancreatic exocrine insufficiency: diagnostic evaluation and pancreatic enzyme replacement therapy. PubMed.
- NCCIH. “Detoxes” and “Cleanses”: What You Need To Know.
- Acosta RD, Cash BD. Clinical effects of colonic cleansing for general health promotion. Am J Gastroenterol. 2009.
- Effect of apple cider vinegar on delayed gastric emptying in type 1 diabetes mellitus: pilot study. PubMed.
- Esophageal injury by apple cider vinegar tablets and product evaluation. PubMed.
- Leaky Gut and the Ingredients That Help Treat It: A Review. PubMed.
- Leaky Gut Syndrome: Myths and Management. PMC.